XRTX Submits Administrative 6-K with No Material Updates

Rhea-AI Filing Summary

XORTX Therapeutics (Nasdaq: XRTX) filed a routine Form 6-K for the month of June 2025. The document is largely administrative, consisting of the cover page, a signature by Chief Executive Officer Allen Davidoff dated June 26, 2025, and an exhibit index referencing Exhibit 99.1 (a news release issued the same day). No financial statements, operational updates, or material corporate events are disclosed within the filing itself.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX Therapeutics Inc.
		(Registrant)
Date: June 26, 2025		By:	/s/ Allen Davidoff
		Name:	Allen Davidoff
		Title:	Chief Executive Officer

EXHIBIT INDEX 

99.1 News release dated June 26, 2025

 

FAQ

What type of filing did XRTX submit on June 29, 2025?

XORTX Therapeutics filed a routine Form 6-K as a foreign private issuer under the Securities Exchange Act of 1934.

Does the June 2025 Form 6-K include financial results for XRTX?

No. The filing is strictly administrative and contains no financial statements or earnings information.